HomeCompareSICRF vs MRK

SICRF vs MRK: Dividend Comparison 2026

SICRF yields 1.06% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $33.5K in total portfolio value
10 years
SICRF
SICRF
● Live price
1.06%
Share price
$103.00
Annual div
$1.09
5Y div CAGR
20.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.2K
Annual income
$787.44
Full SICRF calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — SICRF vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSICRFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SICRF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SICRF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SICRF
Annual income on $10K today (after 15% tax)
$89.95/yr
After 10yr DRIP, annual income (after tax)
$669.32/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, MRK beats the other by $7,927.39/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SICRF + MRK for your $10,000?

SICRF: 50%MRK: 50%
100% MRK50/50100% SICRF
Portfolio after 10yr
$41.0K
Annual income
$5,450.61/yr
Blended yield
13.30%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

SICRF
No analyst data
Altman Z
12.0
Piotroski
7/9
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SICRF buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSICRFMRK
Forward yield1.06%2.81%
Annual dividend / share$1.09$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR20.1%32.7%
Portfolio after 10y$24.2K$57.7K
Annual income after 10y$787.44$10,113.78
Total dividends collected$3.7K$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SICRF vs MRK ($10,000, DRIP)

YearSICRF PortfolioSICRF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$10,827$127.10$11,213$373.04$386.00MRK
2$11,739$154.46$12,667$512.06$928.00MRK
3$12,749$187.97$14,439$708.14$1.7KMRK
4$13,871$229.14$16,640$988.16$2.8KMRK
5$15,122$279.81$19,432$1,394.07$4.3KMRK
6$16,522$342.39$23,057$1,992.90$6.5KMRK
7$18,099$419.92$27,889$2,894.79$9.8KMRK
8$19,882$516.30$34,518$4,286.29$14.6KMRK
9$21,910$636.60$43,912$6,494.35$22.0KMRK
10$24,232$787.44$57,714$10,113.78$33.5KMRK

SICRF vs MRK: Complete Analysis 2026

SICRFStock

SimCorp A/S, together with its subsidiaries, provides investment management solutions for asset management, fund management, insurance, life/pension, central banks, asset servicing, treasury, sovereign wealth, and wealth management companies. It provides SimCorp Dimension, an integrated front-to-back investment management solution; SimCorp Sofia, a front-to-back investment management solution for the Italian insurance market; SimCorp Gain, an enterprise data management solution for reference and market data management; and SimCorp Coric, a solution for client communications and reporting automation. The company also offers front office solutions, including asset, alternative investment, order, and compliance manager; and back office solutions comprising settlement, corporate actions, cash and securities, investment accounting, collateral, general ledger, and fund administration manager. In addition, it provides middle office solutions consisting of strategy, risk analysis, and performance manager; and data and reporting solutions, which include client communications, data warehouse manager, reconciliation, and enterprise data manager. The company has operations in North America, Europe, the Middle East, Africa, and the Asia Pacific. SimCorp A/S was founded in 1971 and is headquartered in Copenhagen, Denmark.

Full SICRF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this SICRF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SICRF vs SCHDSICRF vs JEPISICRF vs OSICRF vs KOSICRF vs MAINSICRF vs JNJSICRF vs ABBVSICRF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.